The SIERRA trial may enable bone marrow transplant even if your AML is not in remission

Learn More About the Sierra Trial

Transplant Can Be an Option for Patients With Active, Relapsed or Refractory Acute Myeloid Leukemia

Learn More About the Sierra Trial

Do I Qualify?

I have AML. Am I eligible for the SIERRA study?

Locations

Find a SIERRA clinical trial site near you

FAQs

Answers to common questions about SIERRA trial

Targeting Acute Myeloid Leukemia

The SIERRA Trial is investigating the use of
131 I apamistamab (Iomab-B) in patients
age 55 and older with active, relapsed or
refractory Acute Myeloid Leukemia (AML)

Learn More About SIERRA Trial

What Is It?

Learn More About 131I apamistamab

131 I apamistamab (Iomab-B) is an investigational drug that targets bone marrow and blood cancer (leukemia) cells. In this clinical trial, it is used to help relapsed or refractory AML patients get ready for bone marrow transplant (BMT)

Learn More About Iomab-B

About AML

Acute Myeloid Leukemia

AML is a cancer of the blood and bone marrow, and is often treated with bone marrow transplant (BMT)